Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 29:11:1130.
doi: 10.3389/fphar.2020.01130. eCollection 2020.

TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma

Ying Wu  1   2 , Han Qi  1   2 , Fei Cao  1   2 , Lujun Shen  1   2 , Shuanggang Chen  1   2 , Lin Xie  1   2 , Tao Huang  1   2 , Ze Song  3 , Danyang Zhou  1   3 , Weijun Fan  1   2
Affiliations

TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma

Ying Wu et al. Front Pharmacol. .

Abstract

Purpose: To investigate the effectiveness and safety of transarterial chemoembolization (TACE) combined with sorafenib and thermal ablation in patients with huge hepatocellular carcinoma (HCC).

Materials and methods: This retrospective study examined 50 patients with huge unresectable HCC treated from January 2009 to December 2015. Among them, 28 cases received TACE-sorafenib treatment (TACE-sorafenib group), and 22 cases received TACE-sorafenib plus thermal ablation treatment (TACE-sorafenib-thermal ablation group). The Overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were compared.

Results: The median follow-up was 13.5 months (ranges 4.2 to 96.7 months). The median OS was significantly longer in the TACE-sorafenib-thermal ablation group than that in the TACE-sorafenib group (20.8 vs. 10.4 months, P=0.003). The median PFS of the ablation and no ablation groups were 4.3 vs. 7.1 months (P=0.546). The treatment modality was an independent predictor of OS (P=0.004). There were no notable drug-related high grade adverse events or permanent adverse sequelae.

Conclusion: TACE-sorafenib-thermal ablation provided extended OS to patients with huge unresectable HCC and could be a better choice than TACE-sorafenib.

Keywords: drug resistance; hepatocellular carcinoma; sorafenib; thermal ablation; transarterial chemoembolization; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival of the transarterial chemoembolization (TACE)‑sorafenib-thermal ablation and TACE-sorafenib groups.
Figure 2
Figure 2
Progression-free survival of the transarterial chemoembolization (TACE)-sorafenib-thermal ablation and TACE-sorafenib groups.
Figure 3
Figure 3
Overall survival of patients with and without vascular invasion/metastasis in the transarterial chemoembolization (TACE)-sorafenib group (A) and the TACE-sorafenib-thermal ablation group (B).
Figure 4
Figure 4
Overall survival of patients who received radiofrequency ablation (RFA) and microwave ablation (MWA) in the transarterial chemoembolization (TACE)-sorafenib-thermal ablation group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abdel-Rahman O., Elsayed Z. A. (2013). Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature. Dig. Dis. Sci. 58 (12), 3389–3396. 10.1007/s10620-013-2872-x - DOI - PubMed
    1. Brown D. B., Gould J. E., Gervais D. A., Goldberg S. N., Murthy R., Millward S. F., et al. (2009). Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J. Vasc. Interv. Radiol. 20 (7 Suppl), S425–S434. 10.1016/j.jvir.2009.04.021 - DOI - PubMed
    1. Cabrera R., Pannu D. S., Caridi J., Firpi R. J., Soldevila-Pico C., Morelli G., et al. (2011). The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment. Pharmacol. Ther. 34 (2), 205–213. 10.1111/j.1365-2036.2011.04697.x - DOI - PMC - PubMed
    1. Chan S. L., Chong C. C., Chan A. W., Poon D. M., Chok K. S. (2016). Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World J. Gastroenterol. 22 (32), 7289–7300. 10.3748/wjg.v22.i32.7289 - DOI - PMC - PubMed
    1. Chen W., Zheng R., Baade P. D., Zhang S., Zeng H., Bray F., et al. (2016). Cancer statistics in China 2015. CA Cancer J. Clin. 66 (2), 115–132. 10.3322/caac.21338 - DOI - PubMed
-